Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.4)
Index Copernicus  – 161.11; MEiN – 140 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2013, vol. 22, nr 6, November-December, p. 785–794

Publication type: original article

Language: English

Proteomic Analysis of the Immunosuppressive Effects of Mesenchymal Stem Cells in a Rat Heart Transplantation Model

Analiza proteomiczna działania immunosupresyjnego mezenchymalnych komórek macierzystych na modelu zwierzęcym z wykorzystaniem serca szczurów

Shuo-Ming Wu1,B,C,D, Wen-Xiong Zhang1,B,C,D, Ming-Hui Wang1,B,C, Hui-Zhong Zhang1,A,E,F, Duo-Guang Wu1,C, Zhi-Juan Zhou2,C, Li-Hua Xiong1,B,C

1 Department of Heart Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, China

2 Department of Heart Surgery, Fifth Affiliated Hospital of Sun Yat-sen University, China


Background. Some reports suggest mesenchymal stem cells (MSCs) have immunosuppressive properties. However, conflicting evidence regarding the role of MSCs has emerged.
Objectives. To gain a better understanding of the immunosuppressive properties of mesenchymal stem cells (MSCs) in a rat heart transplantation model.
Material and Methods. MSCs were obtained from the femoral and tibial bone marrow of Sprague-Dawley rats and cultured. Heart-transplanted rats were allocated into a MSC-treated group and 2 control groups. On postoperative day 7, 1 rat was sacrificed and the pathological changes of heart tissues were assessed. Serum proteomic spectra were generated by surface-enhanced laser desorption/ionization-time-of-flight mass spectrometry (SELDI-TOF-MS).
Results. Rat MSCs displayed the typical spindle-shaped morphology in culture and significantly prolonged the graft survival up to 33.25 ± 2.54 days compared with controls (19.75 ± 1.56 and 11.16 ± 1.34 days, respectively). Pathological analysis showed the inflammatory cell infiltration in the MSC-treated group was significantly reduced. SELDI analysis showed that 5 protein/peptide peaks with M/Z 1272.33, 1986.65, 2323.42, 5375.59 and 12968.11 were up-regulated in the MSC-treated group (P < 0.001).
Conclusion. Donor-derived MSCs clearly alleviate acute rejection following heart transplantation in rats and significantly prolong the isograft survival time

Key words

rat heart transplantation, immunosuppression, mesenchymal stem cells, SELDI ProteinChip, decision tree.

References (22)

  1. Toma JG, McKenzie IA, Bagli D, Miller FD: Isolation and characterization of multipotent skin-derived precursors from human skin. Stem Cells 2005, 23, 727–737.
  2. Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, Alfonso ZC, Fraser JK, Benhaim P, Hedrick MH: Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002, 13, 4279–4295.
  3. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284, 43–47.
  4. Kim YH, Wee YM, Choi MY, Lim DG, Kim SC, Han DJ: Interleukin (IL)-10 induced by CD11b(+) cells and IL-10-activated regulatory T cells play a role in immune modulation of mesenchymal stem cells in rat islet allografts. Mol Med 2011, 17, 697–708.
  5. Wan CD, Cheng R, Wang HB, Liu T: Immunomodulatory effects of mesenchymal stem cells derived from adipose tissues in a rat orthotopic liver transplantation model. Hepatobiliary Pancreat Dis Int 2008, 7, 29–33.
  6. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R, Moseley A, Hoffman R: Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002, 30, 42–48.
  7. Zhou HP, Yi DH, Yu SQ, Sun GC, Cui Q, Zhu HL, Liu JC, Zhang JZ, Wu TJ: Administration of donor-derived mesenchymal stem cells can prolong the survival of rat cardiac allograft. Transplant Proc 2006, 38: 3046–3051.
  8. Crop MJ, Baan CC, Korevaar SS, Ijzermans JN, Alwayn IP, Weimar W, Hoogduijn MJ: Donor-derived mesenchymal stem cells suppress alloreactivity of kidney transplant patients. Transplantation 2009, 87, 896–906.
  9. Casiraghi F, Azzollini N, Cassis P, Imberti B, Morigi M, Cugini D, Cavinato RA, Todeschini M, Solini S, Sonzogni A, Perico N, Remuzzi G, Noris M: Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol 2008, 181, 3933–3946.
  10. Sbano P, Cuccia A, Mazzanti B, Urbani S, Giusti B, Lapini I, Rossi L, Abbate R, Marseglia G, Nannetti G, Torricelli F, Miracco C, Bosi A, Fimiani M, Saccardi R: Use of donor bone marrow mesenchymal stem cells for treatment of skin allograft rejection in a preclinical rat model. Arch Dermatol Res 2008, 300, 115–124.
  11. Inoue S, Popp FC, Koehl GE, Piso P, Schlitt HJ, Geissler EK, Dahlke MH: Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation 2006, 81, 1589–1595.
  12. Stagg J, Galipeau J: Immune plasticity of bone marrow-derived mesenchymal stromal cells. Handb Exp Pharmacol 2007, 45–66.
  13. Noël D, Djouad F, Bouffi C, Mrugala D, Jorgensen C: Multipotent mesenchymal stromal cells and immune tolerance. Leuk Lymphoma 2007, 48, 1283–1289.
  14. Ramasamy R, Fazekasova H, Lam EW, Soeiro I, Lombardi G, Dazzi F: Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle: Transplantation 2007, 83, 71–76.
  15. Nauta AJ, Fibbe WE: Immunomodulatory properties of mesenchymal stromal cells. Blood 2007, 110, 3499– –3506.
  16. Ryan JM, Barry FP, Murphy JM, Mahon BP: Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond) 2005, 2, 8.
  17. Ono K, Lindsey ES: Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg 1969, 57, 225–229.
  18. Lin Q, Peng Q, Yao F, Pan XF, Xiong LW, Wang Y, Geng JF, Feng JX, Han BH, Bao GL, Yang Y, Wang X, Jin L, Guo W, Wang JC: A classification method based on principal components of SELDI spectra to diagnose of lung adenocarcinoma. PLoS One 2012; 7: e34457. DOI: 10.1371/journal.pone.0034457.
  19. Ge Z, Zhu YL, Zhong X, Yu JK, Zheng S: Discovering differential protein expression caused by CagA-induced ERK pathway activation in AGS cells using the SELDI-ProteinChip platform. World J Gastroenterol 2008, 14, 554–562.
  20. Carr CA, Stuckey DJ, Tatton L, Tyler DJ, Hale SJ, Sweeney D, Schneider JE, Martin-Rendon E, Radda GK, Harding SE, Watt SM, Clarke K: Bone marrow-derived stromal cells home to and remain in the infarcted rat heart but fail to improve function: an in vivo cine-MRI study. Am J Physiol Heart Circ Physiol 2008, 295, 533–542.
  21. Bartholomew A, Patil S, Mackay A, Nelson M, Buyaner D, Hardy W, Mosca J, Sturgeon C, Siatskas M, Mahmud N, Ferrer K, Deans R, Moseley A, Hoffman R, Devine SM: Baboon mesenchymal stem cells can be genetically modified to secrete human erythropoietin in vivo. Hum Gene Ther 2001, 12, 1527–1541.
  22. Biancamaria L, Erzsèbet S, Lorenza P, Benedetta M, Giacomo TP, Serena U, Paola Quaranta1, SA, Sergio T, Marcella C, Riccardo S, Bruno N, Franco M: Mesenchymal stem cell-based immunomodulation in allogeneic heterotopic heart-lung transplantation. Transplantation Technologies & Research 2012. 2: p. DOI: 10.4172/2161- -0991.1000107.